Kyntra Bio, Inc.
NASDAQ Global MarketTotal Valuation
Kyntra Bio, Inc. carries a market capitalization of 21.50M, placing it among publicly traded companies globally. Its enterprise value stands at -38.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 21.50M |
| Enterprise Value | -38.75M |
Share Statistics
Kyntra Bio, Inc. currently has 4.05M shares outstanding.
| Shares Outstanding | 4.05M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Kyntra Bio, Inc. trades at a trailing price-to-earnings ratio of 0.17. The price-to-sales ratio is 6.62, and the price-to-book ratio stands at -1.01.
| PE Ratio | 0.17 |
| PS Ratio | 6.62 |
| PB Ratio | -1.01 |
| P/TBV Ratio | -1.01 |
| P/FCF Ratio | -0.80 |
| P/OCF Ratio | -0.80 |
Financial Position
Kyntra Bio, Inc. maintains a current ratio of 2.69, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.69 |
| Quick Ratio | 2.54 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -5.39 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 131.26 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.19 |
Taxes
| Income Tax | -1,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Kyntra Bio, Inc.'s stock has declined approximately -52.33393% over the past 52 weeks. The 50-day moving average sits at 7.09, while the 200-day moving average is 7.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | -52.33393% |
| 50-Day Moving Average | 7.09 |
| 200-Day Moving Average | 7.30 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kyntra Bio, Inc. generated 4.62M in revenue and converted that into 183.19M in net income, yielding earnings per share of -7.64. EBITDA reached -50.03M, while operating income came in at -50.25M.
| Revenue | 4.62M |
| Gross Profit | 289,000.00 |
| Operating Income | -50.25M |
| Pretax Income | -30.91M |
| Net Income | 183.19M |
| EBITDA | -50.03M |
| EBIT | -50.25M |
| Earnings Per Share (EPS) | -7.64 |
Balance Sheet
Total book value stands at -30.14M, with working capital of 60.79M providing operational flexibility.
| Cash & Cash Equivalents | 91.32M |
| Total Debt | N/A |
| Net Debt | -50.64M |
| Equity (Book Value) | -30.14M |
| Book Value Per Share | -7.44 |
| Working Capital | 60.79M |
Cash Flow
Kyntra Bio, Inc. produced -38.05M in operating cash flow over the past twelve months. After subtracting -9,000.00 in capital expenditures, free cash flow totaled -38.06M - equivalent to -9.41 per share.
| Operating Cash Flow | -38.05M |
| Capital Expenditures | -9,000.00 |
| Free Cash Flow | -38.06M |
| FCF Per Share | -9.41 |
Margins
Kyntra Bio, Inc. operates with a gross margin of 6.26, reflecting its pricing power and cost economics. The operating margin of -1,088.33 and net profit margin of 3,967.77 provide insight into operational efficiency.
| Gross Margin | 6.26 |
| Operating Margin | -1,088.33 |
| Pretax Margin | -669.59 |
| Profit Margin | 3,967.77 |
| EBITDA Margin | -1,083.71 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 281.14 |
| FCF Yield | -124.53 |
Stock Splits
Kyntra Bio, Inc.'s most recent stock split took place on June 17, 2025 with a 25:1 split ratio.
| Last Split Date | 6/17/2025 |
| Split Ratio | 25:1 |
Scores
Kyntra Bio, Inc. posts an Altman Z-Score of -24.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -24.38 |